Solid Biosciences Inc. — Director's Dealing 2023

Jun 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2023-04-03

Reporting Person: SMITH IAN F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-03	Common Stock	M	15569	—	Acquired	53239	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-03	Restricted Stock Units	$	M	15569	Disposed		Common Stock (15569)	Direct
2023-06-06	Director Stock Option (Right to Buy)	$6.37	A	9650	Acquired	2033-06-06	Common Stock (9650)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.

F3: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.